Evolution and governance of the biotechnology and pharmaceutical industry of China

被引:22
作者
Wang, Kai [2 ]
Hong, Jin [1 ]
Marinova, Dora [3 ]
Zhu, Liang [2 ]
机构
[1] Univ Sci & Technol China, Sch Management, Hefei 230026, Anhui, Peoples R China
[2] Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei 230026, Anhui, Peoples R China
[3] Curtin Univ Technol, Curtin Univ Sustainabil Policy CUSP, Perth, WA 6845, Australia
基金
澳大利亚研究理事会; 中国国家自然科学基金;
关键词
Biotechnology and pharmaceutical industry; Evolution; Governance; Actor-Networks theory (ANT); INNOVATION; US;
D O I
10.1016/j.matcom.2008.09.001
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The high-speed growth of China's biotechnology industry during the past 20 years presents an excellent opportunity to examine its overall evaluation and governance from the perspective of science and technology policies. Although China's biotechnology industry has achieved tremendous extension both in scale and structure, the strengths it has gained from achievements in research and development activities have been significantly weakened in relation to processes of commercialization. After examining the definition of China's biotechnology industry as well as its evolution, the authors of this paper employ Actor-Networks Theory as a basic theoretical framework to reveal how China's biotechnology industry develops in the form of evolving networks within the country's social context and to identify what kinds of relationships exist among the relevant factors. Our hope is to provide guiding insights for improving the governance of China's biotechnology industry both in policy and in management practices. Crown Copyright (C) 2008 Published by Elsevier B.V. on behalf of IMACS. All rights reserved.
引用
收藏
页码:2947 / 2956
页数:10
相关论文
共 25 条
[1]  
Biagioli M., 1999, SCI STUDIES READER, P137
[2]   China's leap forward in biotechnology - An interview with Zhu Chen, director of the Chinese National Human Genome Centre of Shanghai and Vice President of the Chinese Academy of Sciences [J].
Breithaupt, H ;
Chen, Z .
EMBO REPORTS, 2003, 4 (02) :111-113
[3]  
Callon M., 1986, MAPPING DYNAMICS SCI
[4]  
*COMM NAT DEV PLAN, 2003, REP DEV CHIN BIOT 20
[5]  
Ding H., 2007, BIOINDUSTRY R D CHIN
[6]  
Fang F., 2006, CHINA PHARM IND REPO
[7]   The contrasting roles of government in the development of biotechnology industry in the US and Germany [J].
Giesecke, S .
RESEARCH POLICY, 2000, 29 (02) :205-223
[8]   An analysis of firm-level innovation strategies in the US biotechnology industry [J].
Hall, Linda A. ;
Bagchi-Sen, Sharmistha .
TECHNOVATION, 2007, 27 (1-2) :4-14
[9]  
Hamer D. H., 1989, BIOTECHNOLOGY CHINA, P3
[10]  
HARA T, 2003, INNOVATION PHARM IND, P292